Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a p
The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics.
Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d
Three digital health technologies (DHTs) used to support patients with psychosis can be used by the NHS while additional evidence of their benefits is gathered.
Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a sha
Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.